Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13559139 | 1.00 | LMNA (0.37) | LMNACES2ESR2 | |
| SCHEMBL807045 | 1.00 | LMNA (0.37) | LMNACES2ESR2 | |
| SCHEMBL13635332 | 0.92 | LMNA (0.33) | LMNACES2 | |
| SCHEMBL456619 | 0.87 | — | — | |
| SCHEMBL7526154 | 0.87 | LMNA (0.42) | LMNACES2 | |
| SCHEMBL16216114 | 0.83 | LMNA (0.34) | LMNACES2 | |
| SCHEMBL14942465 | 0.83 | LMNA (0.34) | LMNACES2 | |
| SCHEMBL14922891 | 0.83 | LMNA (0.34) | LMNACES2 | |
| SCHEMBL10005777 | 0.83 | LMNA (0.34) | LMNACES2 | |
| SCHEMBL13448496 | 0.83 | LMNA (0.34) | LMNACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220249395-A1 | PHARMACEUTICAL FORMULATIONS FOR A LIQUID DOSAGE FORM AND A CONTROLLED RELEASE DOSAGE FORM | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2022-08-11 | — | — | US | disclosed |
| US-20190000776-A1 | METHOD FOR TREATING AN AUTOIMMUNE NEUROLOGICAL DISEASE AND/OR NEURODEGENERATIVE DISEASE AND PHARMACEUTICAL FORMULATIONS FOR A LIQUID DOSAGE FORM AND A CONTROLLED RELEASE DOSAGE FORM | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2019-01-03 | — | — | US | disclosed |
| US-9725450-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-08-08 | — | — | US | disclosed |
| US-9616037-B2 | Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use | PIMCO 2664 LIMITED (GB) | 2017-04-11 | — | — | US | disclosed |
| US-20160039822-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2016-02-11 | — | — | US | disclosed |
| US-9187479-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2344449-B1 | ARYL-PHENYL-SULFONAMIDO-CYCLOALKYL COMPOUNDS AND THEIR USE | PIMCO 2664 LTD (GB) | 2015-05-13 | — | — | EP | disclosed |
| US-20140206697-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-07-24 | — | — | US | disclosed |
| US-8680076-B2 | Methods of treatment, improvement and prevention using haloaryl substituted aminopurines | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-03-25 | — | — | US | disclosed |
| US-20130225564-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-08-29 | — | — | US | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20090312320-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HALOARYL SUBSTITUTED AMINOPURINES OR COMPOSITIONS THEREOF | SIGNAL PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| US-7521446-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206697-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, HPRT1 | LMNA 843/4885CES2 4693/4885ESR2 3151/4885 |
| US-20130225564-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, HPRT1 | LMNA 843/4885CES2 4693/4885ESR2 3151/4885 |
| US-20190000776-A1 | METHOD FOR TREATING AN AUTOIMMUNE NEUROLOGICAL DISEASE AND/OR NEURODEGENERATIVE DISEASE AND PHARMACEUTICAL FORMULATIONS FOR A LIQUID DOSAGE FORM AND A CONTROLLED RELEASE DOSAGE FORM | HRH4, AOC3, HRH3 | LMNA 4051/4885CES2 3241/4885ESR2 2572/4885 |
| US-20160039822-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, HPRT1 | LMNA 843/4885CES2 4693/4885ESR2 3151/4885 |
| US-20220249395-A1 | PHARMACEUTICAL FORMULATIONS FOR A LIQUID DOSAGE FORM AND A CONTROLLED RELEASE DOSAGE FORM | HRH4, HRH3, NR4A3 | LMNA 3657/4885CES2 2660/4885ESR2 2180/4885 |
| US-20090312320-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HALOARYL SUBSTITUTED AMINOPURINES OR COMPOSITIONS THEREOF | TPMT, MGMT, SMAD3 | LMNA 1027/4885CES2 4776/4885ESR2 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.